...Everybody, and thank you very much for coming. Those of you here, wonderful to see you. And those many of you online, I really appreciate you taking the time to spend with us today, and hopefully you'll visit with us one on one. Today we're going to talk about biomarkers in epilepsy and our 329 program. I'd like to really encourage you to dig in. This is an important moment for not just for of it actually for the industry. Our pipeline is something very unusual. We have readouts coming later this year. We felt at this moment it was the right time to share more about what we're thinking and how we think the future of epilepsy drug development will be shaped and central to that will be biomarkers. As a public company of course, these are our forward-looking statements. Before we begin, I want to really take a moment to introduce you to the team who's going to be walking you through this. This is the powerhouse that drives of it. First, I'd like to introduce you to Meg Alexander. Meg is of...
